Non-Inferiority gets approval. CEMP is dirt cheap either with non-superiority or with Superiority. What's the problem...there isn't one. Just keep adding at these ridiculous prices.
A true no brainer.After all the data, if good, (COPD, IV,and Gono), EU partner, NDA submission, I am looking at the $75-$100 area. Then BO.$125-$150. After COPD Sept, $50-$60 if good.
When was the 10th patient enrolled? Also if you see the centers accelerating enrollment after a period of time...I look to that as the physicians seeing positive results.
Heading to PHIII not PHII. Back test what? More like no one wants to be in the market right now. That could change. China fears not all that relevant to healthcare sector. Getting to be almost laughable.
It's not a issue. CTIX is wanting results from trials before a partnership. Otherwise you get r*ped. Then $$$ will not be an issue.
Per Mako, that would be an impossible outcome per his short thesis... Based on his on staff "PHD Biochemist" assessment of B the FDA would tell Leo are you kidding. -LOL. If FDA approves, It would be another repudiation of Mako's on staff PHD, who he should fire immediately. I have to say I am getting a kick of this, on how fast the SA hit article has been completely destroyed by many. The FDA would be the final nuclear bomb that vaporizes it.
It's hard to say how many are Mako himself. For example Dr. Ten Bagger, strikes me as Mako. I am sure there were a few of his shorting buds that didn't expect a complete dismantling of their extremely poorly constructed, delusional logic (or just out right lies) short thesis.
K results, new cohort
Combo K trial starting in Italy.
Maybe a partner.
Depending on Stock price Uplisting late 4 qtr.
Mako Research goes long
is behind it. Seeking compensation for shareholder losses.
I would add that they are seeing durations at 11 months now, where a month or two is the norm for very advanced tumors. Stock should be double here.